Close
  Indian J Med Microbiol
 

Figure 2: (a) Dulaglutide naïve group (n = 74), relationship between baseline HbA1c and HbA1c difference at 6 months (Pearson's correlation coefficient of 0.600 (P < 0.001). (b) Dulaglutide naïve group (n = 74), relationship between baseline weight and weight difference at 6 months (Pearson's correlation coefficient 0.320, P value = 0.005). (c) Patients on dulaglutide and not on any SGLT-2 inhibitor (n = 47), relationship between baseline HbA1c and HbA1c difference at 6 months (Pearson's correlation 0.719; P value <0.001). (d) Patients on dulaglutide and not on any SGLT-2 inhibitor (n = 47), relationship between baseline weight and weight difference at 6 months (Pearson's correlation 0.263; P value 0.074)

Figure 2: (a) Dulaglutide naïve group (<i>n</i> = 74), relationship between baseline HbA1c and HbA1c difference at 6 months (Pearson's correlation coefficient of 0.600 (<i>P</i> < 0.001). (b) Dulaglutide naïve group (<i>n</i> = 74), relationship between baseline weight and weight difference at 6 months (Pearson's correlation coefficient 0.320, <i>P</i> value = 0.005). (c) Patients on dulaglutide and not on any SGLT-2 inhibitor (<i>n</i> = 47), relationship between baseline HbA1c and HbA1c difference at 6 months (Pearson's correlation 0.719; <i>P</i> value <0.001). (d) Patients on dulaglutide and not on any SGLT-2 inhibitor (<i>n</i> = 47), relationship between baseline weight and weight difference at 6 months (Pearson's correlation 0.263; <i>P</i> value 0.074)